-
EHA Expert Interview | Professor Zhiming Li: Zanubrutinib Combined with CHOP Shows Superior Efficacy in Newly Diagnosed DLBCL Patients, Especially in the GCB Subtype
Oncology Frontier – Hematology Frontier: At this conference, you presented a study comparing zanubrutinib combined with CHOP versus rituximab combined with CHOP in treating CD20-positive newly diagnosed diffuse large B-cell…
-
EASL Liver Cancer Summit | HNF1A Gene: Unlocking the “Key” to Hepatocellular Carcinoma Risk – Exclusive Interview with Professor Mohamed Abdel Samie
Hepatocellular carcinoma (HCC), one of the most lethal tumors globally, has long been a research hotspot due to its complex pathogenesis involving interactions between genetics, metabolism, and viral infections. Recently, at the 2025 EASL Liver Cancer Summit held in Paris, France, a study by Professor Mohamed Abdel Samie’s team from the Department of Hepatology and…
-
Professor Xichun Hu’s Team: Lerociclib plus letrozole versus placebo plus letrozole in HR+/HER2- advanced or metastatic breast cancer
Study : LEONARDA-2 (Abstract 1052) LEONARDA-2 is a randomized, double-blind, placebo-controlled phase III study that enrolled HR+/HER2- advanced or metastatic breast cancer patients who had not received prior systemic treatment…
-
ASCO GI 2025 | Dr. Zhi Peng: Five-Year Survival Benefits from CheckMate 649 Bring New Hope for a Cure in Gastric Cancer Patients
CheckMate 649 is the first global Phase III trial to successfully evaluate a first-line immunotherapy regimen (nivolumab + chemotherapy) for advanced gastric cancer. The study’s primary results were first unveiled at the 2020 European Society for Medical Oncology (ESMO) Congress, and the pre-specified China subgroup data were presented for the first time at the 2021…
-
EHA Expert Interview | Professors Huilai Zhang and Shiyong Zhou’s Team: Major Advances in Lymphoma Research
Oncology Frontier – Hematology Frontier: Could you talk about your team’s research on the epidemiological characteristics and prognosis of primary gastrointestinal follicular lymphoma (PGI-FL) presented at this EHA meeting (abstract…
-
ASCO China Voice | Prof. Xichun Hu’s Team: Phase II/III Trial of ARX788 vs. Lapatinib + Capecitabine for HER2+ ABC
Study : ACE-Breast-02 (Abstract 1020) ARX788 is a novel anti-HER2 ADC that conjugates to the potent cytotoxic microtubule inhibitor Amberstatin 269 at specific sites. At the 2024 ASCO conference, we…
-
EHA Expert Interview | Professor Jie Jin: Zhejiang University’s Voice Resonates Internationally with GR1803 for RRMM
Oncology Frontier – Hematology Frontier: At this conference, several of your team’s studies were selected. Among them, P961 is about GR1803 (a BCMA×CD3 bispecific antibody) monotherapy for relapsed/refractory multiple myeloma.…
-
Xinghai Forum: Professors Yang Zhang and Kejing Zhang Discuss CDK4/6 Inhibitors in Adjuvant Therapy for HR+ Breast Cancer
Xinghai Forum: Professors Yang Zhang and Kejing Zhang Discuss CDK4/6 Inhibitors in Adjuvant Therapy for HR+ Breast Cancer Prognostic Value of ctDNA Testing in MonarchE Trial Patients and Its Value…
Connecting Medical Expertise through Media